Kajo K, Turčan I, Vallová M, Laboš T, Kajo M, Macháleková K, S Galbavý, Zúbor P
Ústav patológie Slovenskej zdravotníckej univerzity a Onkologického ústavu svätej Alžbety, Bratislava, Slovenská republika.
Ceska Gynekol. 2013 Jun;78(3):263-8.
Carbonic anhydrase IX (CA IX) is one indicator of hypoxia in the tumor and its expression is associated with more aggressive forms of breast cancer. The aim of this study is to point out its own set of correlation between CA IX expression and selected morphological and biological indicators.
Cohort prospective study.
Department of Pathology of Slovak Medical University and St. Elisabeth Cancer Institute, Bratislava, Slovak Republic.
These were 145 cases of breast cancer aged 25 to 85 years (median 59 years) from the Register of the Institute of Pathology and Slovak Medical University and St. Elisabeth Cancer Institute in Bratislava for the period 1. 9. 2012 to 28. 2. 2013. In all cases were examined CA IX, estrogen receptor (ER), progesterone receptor (PR), HER2, p53 and Ki67 by immunohistochemistry. Typing, grading and staging of the disease were evaluated according to the classification systems currently in place.
CA IX expression was demonstrated in 51 cases (35.2%). CA IX positivity correlated with the degree of differentiation (p = 0.0001), with ER status (p <0.0001) and PR (p <0.01) and HER2 (p <0.01) and proliferative activity as measured by Ki67 (p <0.001). HER2-positive cancers and triple-negative cancers were more frequently associated with the expression of CA IX compared with luminal subtypes (p <0.0001). The state of CA IX and age range of the tumor - pT and lymph node status - pN and p53 have not been shown statistically significant correlations.
CA IX examination in breast cancer provides valuable information on the state of hypoxia in the tumor, thereby supplementing view of prognosis of the disease.
碳酸酐酶IX(CA IX)是肿瘤缺氧的一个指标,其表达与侵袭性更强的乳腺癌形式相关。本研究的目的是指出CA IX表达与选定的形态学和生物学指标之间的一系列相关性。
队列前瞻性研究。
斯洛伐克共和国布拉迪斯拉发斯洛伐克医科大学病理学系和圣伊丽莎白癌症研究所。
这些病例来自布拉迪斯拉发病理学研究所、斯洛伐克医科大学和圣伊丽莎白癌症研究所2012年9月1日至2013年2月28日期间的登记册,共145例年龄在25至85岁(中位年龄59岁)的乳腺癌患者。所有病例均通过免疫组织化学检测CA IX、雌激素受体(ER)、孕激素受体(PR)、HER2、p53和Ki67。根据现行分类系统对疾病进行分型、分级和分期评估。
51例(35.2%)显示有CA IX表达。CA IX阳性与分化程度(p = 0.0001)、ER状态(p <0.0001)、PR(p <0.01)、HER2(p <0.01)以及通过Ki67测量的增殖活性(p <0.001)相关。与管腔亚型相比,HER2阳性癌和三阴性癌更常与CA IX表达相关(p <0.0001)。CA IX状态与肿瘤的年龄范围-pT以及淋巴结状态-pN和p53之间未显示出统计学上的显著相关性。
乳腺癌中的CA IX检测可提供有关肿瘤缺氧状态的有价值信息,从而补充对疾病预后的看法。